Compare Stocks: CADL, IDYA, VCYT, and RCUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$11.29 -4.7%	$11.34	$4.35 ▼ $14.00	$863.91M	-0.48	1.50 million shs	1.28 million shs
IDYA IDEAYA Biosciences	$37.46 -5.7%	$37.83	$25.35 ▼ $42.68	$3.29B	-0.07	1.05 million shs	2.24 million shs
RCUS Arcus Biosciences	$26.44 -1.6%	$28.33	$12.15 ▼ $31.74	$3.37B	0.81	1.29 million shs	1.56 million shs
VCYT Veracyte	$43.82 +1.1%	$46.70	$29.45 ▼ $60.91	$3.52B	1.93	1.12 million shs	1.53 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+5.71%	+6.56%	-9.75%	+27.83%	+126.58%
IDYA IDEAYA Biosciences	+2.19%	+5.44%	+0.10%	+9.43%	+53.20%
RCUS Arcus Biosciences	+3.56%	+11.07%	-10.70%	-6.35%	+114.81%
VCYT Veracyte	+4.43%	+8.02%	+2.48%	-23.61%	+27.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$11.29 -4.7%	$11.34	$4.35 ▼ $14.00	$863.91M	-0.48	1.50 million shs	1.28 million shs
IDYA IDEAYA Biosciences	$37.46 -5.7%	$37.83	$25.35 ▼ $42.68	$3.29B	-0.07	1.05 million shs	2.24 million shs
RCUS Arcus Biosciences	$26.44 -1.6%	$28.33	$12.15 ▼ $31.74	$3.37B	0.81	1.29 million shs	1.56 million shs
VCYT Veracyte	$43.82 +1.1%	$46.70	$29.45 ▼ $60.91	$3.52B	1.93	1.12 million shs	1.53 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+5.71%	+6.56%	-9.75%	+27.83%	+126.58%
IDYA IDEAYA Biosciences	+2.19%	+5.44%	+0.10%	+9.43%	+53.20%
RCUS Arcus Biosciences	+3.56%	+11.07%	-10.70%	-6.35%	+114.81%
VCYT Veracyte	+4.43%	+8.02%	+2.48%	-23.61%	+27.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.73	Moderate Buy	$20.14	78.41% Upside
IDYA IDEAYA Biosciences	2.80	Moderate Buy	$52.69	40.66% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	44.88% Upside
VCYT Veracyte	2.82	Moderate Buy	$55.78	27.29% Upside

Current Analyst Ratings Breakdown

Latest CADL, IDYA, VCYT, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	IDYA IDEAYA Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00
9/16/2026	RCUS Arcus Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/15/2026	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	RCUS Arcus Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/9/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/9/2026	IDYA IDEAYA Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$54.00 ➝ $57.00
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/8/2026	RCUS Arcus Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $40.00
9/1/2026	IDYA IDEAYA Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
IDYA IDEAYA Biosciences	$218.71M	15.05	N/A	N/A	$11.67 per share	3.21
RCUS Arcus Biosciences	$247M	13.63	N/A	N/A	$5.84 per share	4.53
VCYT Veracyte	$517.15M	6.81	$1.57 per share	27.88	$16.57 per share	2.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	31.08	28.45	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest CADL, IDYA, VCYT, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.38	16.09	16.09
IDYA IDEAYA Biosciences	N/A	10.45	10.45
RCUS Arcus Biosciences	0.22	3.82	3.82
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
IDYA IDEAYA Biosciences	98.29%
RCUS Arcus Biosciences	92.89%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
IDYA IDEAYA Biosciences	4.70%
RCUS Arcus Biosciences	7.60%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
IDYA IDEAYA Biosciences	145	87.86 million	83.73 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable
VCYT Veracyte	755	80.39 million	79.11 million	Optionable

CADL, IDYA, VCYT, and RCUS Headlines

Recent News About These Companies

John Leite Sells 4,015 Shares of Veracyte (NASDAQ:VCYT) Stock

September 22 at 7:07 PM | marketbeat.com

Veracyte Acquires Convergent Genomics For Up To $180 Million To Add Urinary Tumor DNA Bladder Cancer Platform

September 21 at 12:28 AM | pulse2.comP

Bank of America Corp DE Invests $64.74 Million in Veracyte, Inc. $VCYT

September 20 at 3:20 AM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)

September 19, 2026 | theglobeandmail.com

Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT

September 19, 2026 | marketbeat.com

Jens Holstein Sells 5,000 Shares of Veracyte (NASDAQ:VCYT) Stock

September 18, 2026 | americanbankingnews.com

Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT

September 17, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Director Jens Holstein Sells 5,000 Shares

September 16, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) & Veracyte (NASDAQ:VCYT) Financial Comparison

September 16, 2026 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Analysts

September 16, 2026 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 16, 2026 | marketbeat.com

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

September 15, 2026 | marketscreener.comM

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Veracyte, Inc.: Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 15, 2026 | finanznachrichten.de

Veracyte Buys Convergent Genomics

September 14, 2026 | finance.yahoo.com

Veracyte Acquires Convergent Genomics For $150 Mln In Cash

September 14, 2026 | rttnews.com

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 14, 2026 | globenewswire.com

Why (VCYT) Price Action Is Critical for Tactical Trading

September 13, 2026 | news.stocktradersdaily.comN

Veracyte (NASDAQ:VCYT) Upgraded at UBS Group

September 12, 2026 | marketbeat.com

Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors

September 9, 2026 | gurufocus.com

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

September 9, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL, IDYA, VCYT, and RCUS Company Descriptions

Candel Therapeutics NASDAQ:CADL

$11.29 -0.56 (-4.73%)

Closing price 04:00 PM Eastern

Extended Trading

$11.34 +0.05 (+0.44%)

As of 07:12 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

IDEAYA Biosciences NASDAQ:IDYA

$37.46 -2.25 (-5.67%)

Closing price 04:00 PM Eastern

Extended Trading

$37.46 0.00 (0.00%)

As of 05:24 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Arcus Biosciences NYSE:RCUS

$26.44 -0.43 (-1.62%)

Closing price 03:59 PM Eastern

Extended Trading

$26.39 -0.05 (-0.17%)

As of 04:10 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Veracyte NASDAQ:VCYT

$43.82 +0.46 (+1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$43.13 -0.69 (-1.57%)

As of 07:23 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CADL, IDYA, VCYT, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CADL, IDYA, VCYT, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CADL, IDYA, VCYT, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL, IDYA, VCYT, and RCUS Company Descriptions

Candel Therapeutics NASDAQ:CADL

IDEAYA Biosciences NASDAQ:IDYA

Arcus Biosciences NYSE:RCUS

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CADL, IDYA, VCYT, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CADL, IDYA, VCYT, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CADL, IDYA, VCYT, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL, IDYA, VCYT, and RCUS Company Descriptions

Candel Therapeutics NASDAQ:CADL

IDEAYA Biosciences NASDAQ:IDYA

Arcus Biosciences NYSE:RCUS

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools